Concurrent antibiosis and anti-inflammation against bacterial pneumonia by zinc hexacyanoferrate nanocatalysts. (October 2022)

• Record Type: Journal Article
• Authors: Liu, Peilei; Ji, Penghao; Wang, Liping; Guo, Haiyan; Huo, Minfeng; Shi, Jianlin
• Is Part Of: Biomaterials. Volume 289(2022)
• Publication Date: 2022-10
• Subjects: Nanocatalysts -- Oxidative stress -- Anti-Bacterial -- Pneumonia -- Prussian blue analogue; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121768
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: The bacterial pneumonia has been demonstrated to cause acute and severe pathological lung injury as well as the uncontrollable oxidative cytokine storms. The effective therapeutics against bacterial pneumonia demands highly efficient pathogen elimination, oxidative stress alleviation and anti-inflammation. Nevertheless, current therapeutics fail to achieve these goals by a single medicine with satisfactory performance. Herein, we report a self-assembled zinc-doped prussian blue-analogue – zinc hexacyanoferrate nanocatalysts (ZnPBA NCs ) possessing excellent broad-spectrum anti-bacterial activity and antioxidative catalytic activities against multiple reactive oxygen species (ROS) and the associated cytokine storm as well. By employing various oxidative substances and in vivo murine bacterial pneumoniae models, we verified that the synthetic zinc hexacyanoferrate nanocatalysts could concurrently eliminate the bacterial infection and largely alleviate infection-induced oxidative stress and inflammation, demonstrating the promising clinical application potentials against diverse bacterial infection-related diseases. Graphical abstract: Zinc-doped prussian blue-analogue – zinc hexacyanoferrate nanocatalysts (ZnPBA NCs) were synthesized through facile self-assembly approach. With broad-spectrum anti-bacterial activity and catalytic antioxidative activities, ZnPBA NCs have been demonstrated to exhibit concurrent antibacterial and anti-oxidation/inflammation performance in vitro, as well as high therapeutic consequence against acute bacterial pneumonia in vivo . Image 1